Accuray Incorporated
ARAY Healthcare Medical Devices
Accuray Incorporated’s revenue for fiscal 2026 (year ended June 2026) was $401.9 million, down 12.3% from fiscal 2025. In the quarter to June 2026, revenue fell 20.9%, EPS fell 300.0%, free cash flow grew 117.8% and total debt rose 18.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow ARAY
Accuray Incorporated (ARAY) Piotroski F-score
Accuray Incorporated's Piotroski F-score for fiscal 2026 is 1 out of 9: 1 of nine tests of profitability, leverage and efficiency passed, down from 6 in fiscal 2025.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2026 | 1 | (5.00) |
| FY2025 | 6 | 3.00 |
| FY2024 | 3 | (2.00) |
| FY2023 | 5 | 2.00 |
| FY2022 | 3 | (1.00) |
| FY2021 | 4 | 0.00 |
| FY2020 | 4 | 2.00 |
| FY2019 | 2 | (4.00) |
| FY2018 | 6 | 3.00 |
| FY2017 | 3 | — |
How fiscal 2026’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (10.77%) | (0.34%) | Fail | 0 |
| Positive operating cash flow | (6.98m) | 2.86m | Fail | 0 |
| Rising return on assets | (10.77%) | (0.34%) | Fail | 0 |
| Cash flow above net income | 42.21m | 4.45m | Pass | 1 |
| Falling long-term leverage | 0.32 | 0.26 | Fail | 0 |
| Rising current ratio | 1.50 | 1.65 | Fail | 0 |
| No new shares issued | 122,635,000 | 102,768,000 | Fail | 0 |
| Rising gross margin | 27.73% | 32.05% | Fail | 0 |
| Rising asset turnover | 0.88 | 0.98 | Fail | 0 |
| Piotroski F-score | Weak — most fundamentals deteriorated | 1 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| NSPR InspireMD, Inc. compare | 5 |
| HSCS HeartSciences Inc. compare | 4 |
| LFWD Lifeward Ltd. compare | 4 |
| ALUR Allurion Technologies, Inc. compare | 2 |
| PAVM PAVmed Inc. compare | 2 |
| ARAY Accuray Incorporated | 1 |
| PMI Flag Ship Acquisition Corp compare | — |
| MODD Modular Medical, Inc. compare | — |
| BDMD Baird Medical Investment Holdings Limited compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover